Covid-19 roundup: EMA offers early access to Pfizer's pill Paxlovid; Valneva fires back with booster data of its own

Paul Schloesser

Associate Editor

Nicole DeFeudis

Editor

Zachary Brennan

Senior Editor

The EMA said Thursday that European countries can begin to use Pfizer’s Covid-19 treatment pill Paxlovid, even though it is not yet authorized in the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: EMA offers early access to Pfizer's pill Paxlovid; Valneva fires back with booster data of its own

Paul Schloesser

Associate Editor

Nicole DeFeudis

Editor

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

Covid-19 roundup: EMA of­fers ear­ly ac­cess to Pfiz­er's pill Paxlovid; Val­ne­va fires back with boost­er da­ta of its own

Associate Editor

Editor

Senior Editor

Sign up to read this article for free.

Covid-19 roundup: EMA offers early access to Pfizer's pill Paxlovid; Valneva fires back with booster data of its own